TR199700522A2 - Mirtazapin ve bir ya da daha çok seçiçi serotonin tekrar-emme inhibitörlerini içeren farmasötik bilesim. - Google Patents
Mirtazapin ve bir ya da daha çok seçiçi serotonin tekrar-emme inhibitörlerini içeren farmasötik bilesim.Info
- Publication number
- TR199700522A2 TR199700522A2 TR97/00522A TR9700522A TR199700522A2 TR 199700522 A2 TR199700522 A2 TR 199700522A2 TR 97/00522 A TR97/00522 A TR 97/00522A TR 9700522 A TR9700522 A TR 9700522A TR 199700522 A2 TR199700522 A2 TR 199700522A2
- Authority
- TR
- Turkey
- Prior art keywords
- pharmaceutical composition
- mirtazapine
- composition containing
- serotonin reuptake
- reuptake inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Bulus, mirtazapini, bir seçici serotonin tekrar-emme inhibitörünü (SSRI) ve farmasötik açidan kabul edilebilir yardimci maddeleri içeren bir farmasitök bilesime iliskindir. Özelde, SSRI, flüoksetin, flüvoksamin, sitalopram, seriklamin, femoksetin, sertralin, paroksetin, ifoksetin, siyanodotiepin ve litoksetinden seçilmektedir. Depresan hastalarin iyilestirilmesi için kullanilabilecek bilesim, tek basina SSRI ya da mirtazapin ile hastalarin iyilestirilmesinin kaydettigi yan etkilerden daha az yan etkiye sahip bulunmaktadir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96201703 | 1996-06-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
TR199700522A3 TR199700522A3 (tr) | 1998-01-21 |
TR199700522A2 true TR199700522A2 (tr) | 1998-01-21 |
Family
ID=8224094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR97/00522A TR199700522A2 (tr) | 1996-06-19 | 1997-06-19 | Mirtazapin ve bir ya da daha çok seçiçi serotonin tekrar-emme inhibitörlerini içeren farmasötik bilesim. |
Country Status (25)
Country | Link |
---|---|
US (1) | US5977099A (tr) |
JP (2) | JP4925074B2 (tr) |
KR (1) | KR100481254B1 (tr) |
CN (1) | CN1132581C (tr) |
AR (1) | AR007609A1 (tr) |
AT (1) | ATE213159T1 (tr) |
AU (1) | AU727851B2 (tr) |
BR (1) | BR9703624A (tr) |
CA (1) | CA2208199C (tr) |
CZ (1) | CZ290691B6 (tr) |
DE (1) | DE69710390T2 (tr) |
DK (1) | DK0813873T3 (tr) |
ES (1) | ES2172744T3 (tr) |
HK (1) | HK1006081A1 (tr) |
HU (1) | HU225534B1 (tr) |
ID (1) | ID17051A (tr) |
IL (1) | IL121076A (tr) |
NO (1) | NO313177B1 (tr) |
NZ (1) | NZ328113A (tr) |
PL (1) | PL188520B1 (tr) |
PT (1) | PT813873E (tr) |
RU (1) | RU2181287C2 (tr) |
SG (1) | SG60073A1 (tr) |
TR (1) | TR199700522A2 (tr) |
ZA (1) | ZA975335B (tr) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
KR20010032009A (ko) * | 1997-11-14 | 2001-04-16 | 에프.지.엠. 헤르만스 ; 이.에이치. 리링크 | 수면성 무호흡의 치료에 미타자핀을 사용하는 방법 |
US6960577B2 (en) * | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
US6727283B2 (en) | 1998-10-13 | 2004-04-27 | Pfizer Inc. | Sertraline oral concentrate |
US6575147B2 (en) * | 1999-02-25 | 2003-06-10 | Go-Tec | Internal combustion system adapted for use of a dual fuel composition including acetylene |
AU781221B2 (en) * | 1999-04-19 | 2005-05-12 | Teva Pharmaceutical Industries Ltd. | Novel synthesis and crystallization of piperazine ring-containing compounds |
US6545149B2 (en) | 1999-04-19 | 2003-04-08 | Teva Pharmaceutical Industries Ltd. | Synthesis and crystallization of piperazine ring-containing compounds |
US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
US6759437B2 (en) * | 1999-10-04 | 2004-07-06 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
JP2003520237A (ja) * | 2000-01-19 | 2003-07-02 | アクゾ・ノベル・エヌ・ベー | 鬱病及び関連疾患を治療するためのミルトラザピン及びジェピロンを含有する配合剤 |
WO2002036113A1 (en) * | 2000-11-01 | 2002-05-10 | Respiratorius Ab | Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4) |
ATE380884T1 (de) * | 2001-02-12 | 2007-12-15 | Organon Nv | Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind. |
US20030105082A1 (en) * | 2001-12-03 | 2003-06-05 | Murphy Greer Marechal | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
US6399310B1 (en) | 2001-02-12 | 2002-06-04 | Akzo Nobel N.V. | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
EP1490073A4 (en) * | 2002-03-21 | 2006-02-01 | Martin C Hinz | SEGMENT OPTIMIZATION TECHNOLOGY FOR THE SEROTONIN AND CATECHOLAMINE SYSTEM |
US20070293571A1 (en) * | 2006-06-08 | 2007-12-20 | Hinz Martin C | Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes |
US20090311795A1 (en) * | 2002-03-21 | 2009-12-17 | Hinz Martin C | Bilateral control of functions traditionally regulated by only serotonin or only dopamine |
AR042806A1 (es) * | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
CN1726039B (zh) | 2002-12-27 | 2010-08-18 | 大塚制药株式会社 | 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂 |
BRPI0407619A (pt) * | 2003-02-21 | 2006-03-01 | Martin C Hinz | tecnologia de otimização de segmento de sistema serotonina e catecolamina |
TW200502222A (en) * | 2003-04-02 | 2005-01-16 | Novartis Ag | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
ES2760464T3 (es) | 2003-04-29 | 2020-05-14 | Nalpropion Pharmaceuticals Inc | Composiciones para afectar a la pérdida de peso |
US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
US7838029B1 (en) | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
WO2005023767A2 (en) | 2003-09-10 | 2005-03-17 | Brentwood Equities Ltd. | Diastereomers of 4-aryloxy-3-hydroxypiperidines |
US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
TW200538100A (en) * | 2004-04-21 | 2005-12-01 | Akzo Nobel Nv | Mirtazapine salts |
US20060039866A1 (en) * | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders |
EP1827450A4 (en) * | 2004-11-17 | 2009-04-22 | Cypress Bioscience Inc | METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE |
CA2585317C (en) * | 2004-11-19 | 2015-02-24 | N.V. Organon | Drug combination for the treatment of depression and related disorders comprising a selective serotonin reuptake inhibitor |
BRPI0618918B8 (pt) | 2005-11-22 | 2021-05-25 | Nalpropion Pharmaceuticals Llc | uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
CN101573103A (zh) | 2006-11-09 | 2009-11-04 | 奥雷西根治疗公司 | 用于施用重量减轻药物的单位剂量包装和方法 |
US8088786B2 (en) | 2006-11-09 | 2012-01-03 | Orexigen Therapeutics, Inc. | Layered pharmaceutical formulations |
WO2008157094A1 (en) * | 2007-06-13 | 2008-12-24 | Cypress Bioscience, Inc. | Improving the tolerability of mirtazapine and a second active by using them in combination |
CN101332193B (zh) * | 2007-06-29 | 2012-12-12 | 杭州民生药业有限公司 | 一种马来酸氟伏沙明药物组合物的制备方法 |
WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
US8768578B2 (en) | 2009-06-09 | 2014-07-01 | Sumitomo Heavy Industries, Ltd. | Hybrid excavator and method of controlling hybrid excavator |
WO2011059207A2 (en) * | 2009-11-13 | 2011-05-19 | Green Cross Corporation | Arylpiperazine-containing purine derivatives and uses thereof |
KR20120124423A (ko) | 2010-01-11 | 2012-11-13 | 오렉시젠 세러퓨틱스 인크. | 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법 |
CN102000334B (zh) * | 2010-10-15 | 2012-02-22 | 北京大学 | 用于治疗抑郁症的复方制剂 |
RU2475235C2 (ru) * | 2011-03-15 | 2013-02-20 | Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" | Фармацевтическая композиция для профилактики и лечения депрессивных состояний |
AR085840A1 (es) * | 2011-04-05 | 2013-10-30 | Otsuka Pharma Co Ltd | Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona |
PL2858640T3 (pl) | 2012-06-06 | 2020-10-05 | Nalpropion Pharmaceuticals Llc | Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL189199C (nl) * | 1975-04-05 | 1993-02-01 | Akzo Nv | Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten. |
AU8770282A (en) * | 1981-08-27 | 1983-03-03 | Shaun R. Coughlin | Composition for the treatment of atherosclerosis |
US4940585A (en) * | 1989-02-17 | 1990-07-10 | Hapworth William E | Method for the treatment of nicotine withdrawal syndrome |
EP0431663B1 (en) * | 1989-12-06 | 1994-01-12 | Akzo Nobel N.V. | Stabilized solutions of psychotropic agents |
US5208261A (en) * | 1989-12-06 | 1993-05-04 | Akzo N.V. | Stabilized solutions of psychotropic agents |
US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
IL123716A (en) * | 1997-03-27 | 2001-03-19 | Akzo Nobel Nv | Therapeutic combinations of mirtazapine and an antipsychotic agent |
DE69811378T2 (de) * | 1997-10-03 | 2004-02-12 | Cary Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) | Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion |
-
1997
- 1997-06-13 IL IL12107697A patent/IL121076A/xx not_active IP Right Cessation
- 1997-06-16 US US08/876,346 patent/US5977099A/en not_active Expired - Fee Related
- 1997-06-16 SG SG1997002068A patent/SG60073A1/en unknown
- 1997-06-17 ES ES97201853T patent/ES2172744T3/es not_active Expired - Lifetime
- 1997-06-17 AT AT97201853T patent/ATE213159T1/de not_active IP Right Cessation
- 1997-06-17 NZ NZ328113A patent/NZ328113A/en unknown
- 1997-06-17 DE DE69710390T patent/DE69710390T2/de not_active Expired - Fee Related
- 1997-06-17 CZ CZ19971870A patent/CZ290691B6/cs not_active IP Right Cessation
- 1997-06-17 ZA ZA9705335A patent/ZA975335B/xx unknown
- 1997-06-17 PT PT97201853T patent/PT813873E/pt unknown
- 1997-06-17 DK DK97201853T patent/DK0813873T3/da active
- 1997-06-18 PL PL97320628A patent/PL188520B1/pl not_active IP Right Cessation
- 1997-06-18 CA CA002208199A patent/CA2208199C/en not_active Expired - Fee Related
- 1997-06-18 HU HU9701068A patent/HU225534B1/hu not_active IP Right Cessation
- 1997-06-18 RU RU97110083/14A patent/RU2181287C2/ru not_active IP Right Cessation
- 1997-06-18 BR BR9703624A patent/BR9703624A/pt not_active Application Discontinuation
- 1997-06-18 KR KR1019970025307A patent/KR100481254B1/ko not_active IP Right Cessation
- 1997-06-18 NO NO19972816A patent/NO313177B1/no unknown
- 1997-06-19 AR ARP970102687A patent/AR007609A1/es active IP Right Grant
- 1997-06-19 CN CN97115549A patent/CN1132581C/zh not_active Expired - Fee Related
- 1997-06-19 AU AU26129/97A patent/AU727851B2/en not_active Ceased
- 1997-06-19 ID IDP972117A patent/ID17051A/id unknown
- 1997-06-19 JP JP16257697A patent/JP4925074B2/ja not_active Expired - Fee Related
- 1997-06-19 TR TR97/00522A patent/TR199700522A2/tr unknown
-
1998
- 1998-06-16 HK HK98105337A patent/HK1006081A1/xx not_active IP Right Cessation
-
2008
- 2008-12-12 JP JP2008317326A patent/JP2009137970A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR199700522A2 (tr) | Mirtazapin ve bir ya da daha çok seçiçi serotonin tekrar-emme inhibitörlerini içeren farmasötik bilesim. | |
AP2002002481A0 (en) | Biaryl ether derivatives useful as monoamine reuptake inhibitors. | |
ES2192227T3 (es) | Composiciones farmaceuticas orales con liberacion retardada de inhibidores reversibles de las bombas de protones. | |
SE9800836D0 (sv) | New Compounds | |
RS50924B (sr) | Oralni dozni oblici propiverina ili njegovih farmaceutski prihvatljivih soli sa produženim oslobađanjem aktivne materije | |
NO20073654L (no) | Blandinger og fremgangsmater for a fremme sarheling og vevsregenerering | |
AP2001002252A0 (en) | Monoamine reuptake inhibitors for treatment of CNS disorders. | |
UY28041A1 (es) | Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial. | |
NO20014485L (no) | Nye forbindelser og sammensetninger som proteaseinhibitorer | |
RS20050392A (en) | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | |
ES2196190T3 (es) | Inhibidores de metaloproteinasas matriciales, con hidroxamato bifenlico. | |
ATE409065T1 (de) | Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten | |
NO20061083L (no) | Kombinasjoner omfattende alfa-2-delta ligander og serotonin/noradrenalin gjenopptaksinhibitorer | |
DK1370260T3 (da) | Azoler, som malonyl-coa-decarboxylaseinhibitorer anvendelige som mataboliske modulatorer | |
DE69725860D1 (de) | PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN | |
DE69725345D1 (de) | Verwendung von 5-ht4 antagonisten zur überwindung der gastrointestinalen beschädigung, die durch inhibitoren der serotonin-wiederaufnahme hervorgerufen werden | |
PT1185649E (pt) | Promotor do gene da miostatina e inibicao da sua activacao | |
IS5274A (is) | Lækningameðferð, sem felst í CD 154 hindrun, við lækningaprótínstálmaheilkenni | |
ES2138595T3 (es) | Inhibidores de citoquinas. | |
DK1487482T3 (da) | DNA-vaccine mod prolifererende endotelceller og fremgangsmåder til anvendelse deraf | |
AR038143A1 (es) | Agonistas del receptor 2 del factor liberador de la corticotropina | |
ME00549B (me) | Upotreba inhibitora il-18 za liječenje i/ili prevenciju srčanih oboljenja | |
AR026901A1 (es) | Peptidos con n-alquilacion que tienen actividad antiangiogenica | |
De Kimpe et al. | Reversal of bradykinin-induced relaxation to contraction after interferon-γ in bovine isolated mesenteric arteries | |
PE99699A1 (es) | Composicion que comprende un inhibidor selectivo de la reabsorcion de serotonina y un �-bloqueante |